Ironwood Pharmaceuticals News and Activities
Presence
Ironwood Pharmaceuticals develops and sells prescription medicines for gastrointestinal and rare diseases. Its products and services support patients, healthcare providers, and specialty care markets in the United States.
Ironwood Pharmaceuticals products and services overview:
- Prescription medicines
- Digestive health
- Rare disease
- Drug development
Revenue: ~$393 million
Employees: 300
Headquarters: Boston, United States (USA)
Ironwood Pharmaceuticals is one of the...
Ironwood Pharmaceuticals is a company listed under the stock ticker IRWD (US).
Executives
View the org chart displaying its 26 main executives
Most searched biographies at Ironwood Pharmaceuticals
- Thomas McCourt, Chief Executive Officer and Director
- Mark Currie, Director
- Julie McHugh, Chairman of the Board
Popular executive movements at Ironwood Pharmaceuticals
- Ronald Silver who was Senior Vice President, Corporate Controller and Chief Accounting officer, becomes Senior Vice President, Corporate Controller, Chief Accounting officer and Interim Chief Financial Officer (posted on May 15 2026).
- Greg Martini, Chief Financial Officer, has left the company (posted on May 14 2026).
Create your alert
to follow the executive moves at Ironwood Pharmaceuticals.
Pharmaceuticals
Ironwood Pharmaceuticals has 1,918 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).
Popular M&A news in Pharmaceuticals
- Ipsen has announced the acquisition of Kartos Therapeutics (posted on July 3 2026).
- Ipsen has announced the acquisition of Memo Therapeutics (posted on July 1 2026).
- Hanmi has acquired Aptose Biosciences (posted on July 1 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Ironwood Pharmaceuticals
- FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
- Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
- Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
- Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
- Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
- Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
- Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
- View more press releases Close
Social media about Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Ironwood Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
